{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:09:33Z","timestamp":1785906573218,"version":"3.56.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018935","name":"Universit\u00e4tsklinikum Erlangen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018935","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The yearly incidence of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) continues to rise in the ongoing skin cancer epidemic. Mousa and colleagues have previously highlighted the crucial role of the immune system in the development and progression of both tumor types. Therefore, immune cells in close proximity to, or even infiltrating, the tumor should be of particular interest. Previously, we demonstrated differential expression of immune checkpoint markers, including both activating and inhibitory markers, between BCC and cSCC. The present study aims to further investigate the tumor microenvironment, with a focus on T cells, macrophages, and dendritic cells, among others. Furthermore, we analyzed possible associations between cSCC marker expression and clinicopathological data. In order to evaluate the expression levels and topographic distribution profiles of CD4, CD8, Foxp3, CD68, CD163, and CD11c, tissue microarrays of the invasive front as well as the tumor core of BCC and cSCC samples were analyzed. Chromogenic immunohistochemistry was performed, and the labeling index was determined using QuPath. Stroma cell labeling indices of CD4**, CD8*, Foxp3*, CD68*, CD163**, and CD11c* were significantly higher in both the tumor core and the invasive front of cSCC samples as compared to BCC (*<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; **<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.050). In cSCC, the ratios of CD163\/CD68 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and CD163\/CD11c (<jats:italic>p<\/jats:italic>\u2009=\u20090.001) were markedly elevated. The invasive front of both tumor entities showed higher expression levels of all immune markers compared to the tumor core, when significant levels were reached. Lastly, an association between cSCC sLI CD4 and T status (<jats:italic>p<\/jats:italic>\u2009=\u20090.011), CD11c and N status (<jats:italic>p<\/jats:italic>\u2009=\u20090.041), CD68 and infiltrations depth (<jats:italic>p<\/jats:italic>\u2009=\u20090.018), as well as CD8 and CD11c and previous tumor (<jats:italic>p<\/jats:italic>\u2009=\u20090.006; <jats:italic>p<\/jats:italic>\u2009=\u20090.029, respectively) was observed. This study provides a comprehensive analysis of the tumor microenvironment (TME) of BCC and cSCC, emphasizing the distinct expression patterns of the TME with regard to T cell and macrophage-associated markers. The cSCC TME exhibited higher expression levels of all investigated markers, predominantly at the invasive front rather than the tumor core. Further, more comprehensive analysis of these TMEs is required to understand their impact on clinicopathological data, response to immunotherapy and predictive ability.<\/jats:p>","DOI":"10.1038\/s41598-025-22486-1","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:50:29Z","timestamp":1760014229000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative profiling of T cell and macrophage subsets in cutaneous squamous cell carcinoma and basal cell carcinoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Linus","family":"Winter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Ries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Trumet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol Immanuel","family":"Geppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Scholtysek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Olmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Kesting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"22486_CR1","doi-asserted-by":"publisher","first-page":"114074","DOI":"10.1016\/j.ejca.2024.114074","volume":"204","author":"C Garbe","year":"2024","unstructured":"Garbe, C. et al. Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them. Eur. J. Cancer. 204, 114074 (2024).","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"22486_CR2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/j.1365-2133.2003.05554.x","volume":"149","author":"A Katalinic","year":"2003","unstructured":"Katalinic, A., Kunze, U. & Sch\u00e4fer, T. Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br. J. Dermatol. 149 (6), 1200\u20131206 (2003).","journal-title":"Br. J. Dermatol."},{"issue":"12","key":"22486_CR3","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","volume":"5","author":"C Fitzmaurice","year":"2019","unstructured":"Fitzmaurice, C. et al. Global, Regional, and National cancer Incidence, Mortality, years of life Lost, years lived with Disability, and Disability-Adjusted life-Years for 29 cancer Groups, 1990 to 2017: A systematic analysis for the global burden of disease study. JAMA Oncol. 5 (12), 1749\u20131768 (2019).","journal-title":"JAMA Oncol."},{"key":"22486_CR4","doi-asserted-by":"crossref","unstructured":"Roky, A. H. et al. Overview of Skin Cancer Types and Prevalence Rates across Continents (Cancer Pathogenesis and Therapy, 2024).","DOI":"10.1016\/j.cpt.2024.08.002"},{"issue":"1","key":"22486_CR5","first-page":"110","volume":"48","author":"AR Ciuciulete","year":"2022","unstructured":"Ciuciulete, A. R. et al. Non-Melanoma skin cancer: statistical associations between clinical parameters. Curr. Health Sci. J. 48 (1), 110\u2013115 (2022).","journal-title":"Curr. Health Sci. J."},{"issue":"2","key":"22486_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jaad.2018.03.060","volume":"80","author":"MC Cameron","year":"2019","unstructured":"Cameron, M. C. et al. Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J. Am. Acad. Dermatol. 80 (2), 303\u2013317 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"22486_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.7861\/clinmedicine.16-1-62","volume":"16","author":"LL Griffin","year":"2016","unstructured":"Griffin, L. L., Ali, F. R. & Lear, J. T. Non-melanoma skin cancer. Clin. Med. (Lond). 16 (1), 62\u201365 (2016).","journal-title":"Clin. Med. (Lond)"},{"key":"22486_CR8","doi-asserted-by":"crossref","unstructured":"Mousa, A. M. et al. Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC). Cells, 13(19). (2024).","DOI":"10.3390\/cells13191615"},{"issue":"1","key":"22486_CR9","doi-asserted-by":"publisher","first-page":"15705","DOI":"10.1038\/s41598-021-94435-7","volume":"11","author":"M Ciazynska","year":"2021","unstructured":"Ciazynska, M. et al. Author correction: the incidence and clinical analysis of non\u2013melanoma skin cancer. Sci. Rep. 11 (1), 15705 (2021).","journal-title":"Sci. Rep."},{"issue":"16","key":"22486_CR10","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson, N. M. & Simon, M. C. The tumor microenvironment. Curr. Biol. 30 (16), R921\u2013r925 (2020).","journal-title":"Curr. Biol."},{"key":"22486_CR11","doi-asserted-by":"crossref","unstructured":"Winter, L. et al. Comparative Analysis of Inhibitory and Activating Immune Checkpoints PD-1, PD-L1, CD28, and CD86 in Non-Melanoma Skin Cancer. Cells, 13(18). (2024).","DOI":"10.3390\/cells13181569"},{"key":"22486_CR12","doi-asserted-by":"publisher","first-page":"809687","DOI":"10.3389\/fonc.2022.809687","volume":"12","author":"G Frohwitter","year":"2022","unstructured":"Frohwitter, G. et al. Macrophage and T-Cell infiltration and topographic immune cell distribution in Non-Melanoma skin cancer of the head and neck. Front. Oncol. 12, 809687 (2022).","journal-title":"Front. Oncol."},{"issue":"1","key":"22486_CR13","doi-asserted-by":"publisher","first-page":"e1364828","DOI":"10.1080\/2162402X.2017.1364828","volume":"7","author":"S Simon","year":"2017","unstructured":"Simon, S. & Labarriere, N. PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy? Oncoimmunology 7 (1), e1364828 (2017).","journal-title":"Oncoimmunology"},{"issue":"5","key":"22486_CR14","first-page":"5399","volume":"18","author":"Y Zheng","year":"2019","unstructured":"Zheng, Y., Fang, Y. C. & Li, J. PD-L1 expression levels on tumor cells affect their immunosuppressive activity. Oncol. Lett. 18 (5), 5399\u20135407 (2019).","journal-title":"Oncol. Lett."},{"key":"22486_CR15","doi-asserted-by":"publisher","first-page":"765036","DOI":"10.3389\/fimmu.2021.765036","volume":"12","author":"J Xing","year":"2021","unstructured":"Xing, J. et al. The expression of CD28 and its synergism on the immune response of flounder (Paralichthys olivaceus) to Thymus-Dependent antigen. Front. Immunol. 12, 765036 (2021).","journal-title":"Front. Immunol."},{"issue":"10","key":"22486_CR16","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1182\/blood.V91.10.3892","volume":"91","author":"RE Ryncarz","year":"1998","unstructured":"Ryncarz, R. E. & Anasetti, C. Expression of CD86 on human marrow CD34(+) cells identifies immunocompetent committed precursors of macrophages and dendritic cells. Blood 91 (10), 3892\u20133900 (1998).","journal-title":"Blood"},{"key":"22486_CR17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3389\/fimmu.2017.00292","volume":"8","author":"M Wieczorek","year":"2017","unstructured":"Wieczorek, M. et al. Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation. Front. Immunol. 8, 292 (2017).","journal-title":"Front. Immunol."},{"issue":"2","key":"22486_CR18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov, H. et al. Cytotoxic CD8\u2009+\u2009T cells in cancer and cancer immunotherapy. Br. J. Cancer. 124 (2), 359\u2013367 (2021).","journal-title":"Br. J. Cancer"},{"key":"22486_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-1-4419-1599-3_2","volume":"665","author":"CH Kim","year":"2009","unstructured":"Kim, C. H. FOXP3 and its role in the immune system. Adv. Exp. Med. Biol. 665, 17\u201329 (2009).","journal-title":"Adv. Exp. Med. Biol."},{"issue":"6","key":"22486_CR20","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00428-020-02855-z","volume":"477","author":"T Jamiyan","year":"2020","unstructured":"Jamiyan, T. et al. CD68- and CD163-positive tumor-associated macrophages in triple negative cancer of the breast. Virchows Arch. 477 (6), 767\u2013775 (2020).","journal-title":"Virchows Arch."},{"key":"22486_CR21","doi-asserted-by":"crossref","unstructured":"Martin, A. W. Chap. 6 - Immunohistology of Non-Hodgkin Lymphoma, in Diagnostic Immunohistochemistry (Third Edition), D.J. Dabbs, Editor. W.B. Saunders: Philadelphia. pp. 156\u2013188. (2011).","DOI":"10.1016\/B978-1-4160-5766-6.00010-8"},{"issue":"3","key":"22486_CR22","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.numecd.2015.12.005","volume":"26","author":"E Vianello","year":"2016","unstructured":"Vianello, E. et al. Epicardial adipocyte hypertrophy: association with M1-polarization and toll-like receptor pathways in coronary artery disease patients. Nutr. Metabolism Cardiovasc. Dis. 26 (3), 246\u2013253 (2016).","journal-title":"Nutr. Metabolism Cardiovasc. Dis."},{"issue":"3","key":"22486_CR23","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/bjc.2015.212","volume":"113","author":"M Weber","year":"2015","unstructured":"Weber, M. et al. Macrophage polarisation changes within the time between diagnostic biopsy and tumour resection in oral squamous cell carcinomas\u2013an immunohistochemical study. Br. J. Cancer. 113 (3), 510\u2013519 (2015).","journal-title":"Br. J. Cancer"},{"issue":"7","key":"22486_CR24","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.jcms.2014.01.035","volume":"42","author":"M Weber","year":"2014","unstructured":"Weber, M. et al. Small oral squamous cell carcinomas with nodal lymphogenic metastasis show increased infiltration of M2 polarized macrophages\u2013an immunohistochemical analysis. J. Craniomaxillofac. Surg. 42 (7), 1087\u20131094 (2014).","journal-title":"J. Craniomaxillofac. Surg."},{"issue":"1","key":"22486_CR25","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7 (1), 16878 (2017).","journal-title":"Sci. Rep."},{"key":"22486_CR26","unstructured":"Cohen, J. & Cohen, J. W. Statistical Power Analysis for the Behavioral Sciences 2. edn (Erlbaum, 1988)."},{"issue":"4","key":"22486_CR27","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1111\/bjd.17170","volume":"179","author":"SG Keohane","year":"2018","unstructured":"Keohane, S. G. et al. New 8th edition of TNM staging and implications for skin cancer. Br. J. Dermatol. 179 (4), e179\u2013e179 (2018).","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"22486_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 71 (3), 209\u2013249 (2021).","journal-title":"Cancer J. Clin."},{"key":"22486_CR29","doi-asserted-by":"crossref","unstructured":"Wang, L. et al. Hot and cold tumors: Immunological features and the therapeutic strategies. MedComm 2023. 4(5): p. e343. (2020).","DOI":"10.1002\/mco2.343"},{"issue":"12","key":"22486_CR30","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman, W. H. et al. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14 (12), 717\u2013734 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"22486_CR31","doi-asserted-by":"publisher","unstructured":"Melssen, M. M. et al. Barriers to immune cell infiltration in tumors. J. Immunother Cancer, 11(4),e006401 https:\/\/doi.org\/10.1136\/jitc-2022-006401 (2023).","DOI":"10.1136\/jitc-2022-006401"},{"issue":"1","key":"22486_CR32","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu, B. et al. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal. Transduct. Target. Therapy. 9 (1), 274 (2024).","journal-title":"Signal. Transduct. Target. Therapy"},{"issue":"1","key":"22486_CR33","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das, S. & Johnson, D. B. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J. Immunother. Cancer. 7 (1), 306 (2019).","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"22486_CR34","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"Migden, M. R. et al. PD-1 Blockade with Cemiplimab in advanced cutaneous Squamous-Cell carcinoma. N Engl. J. Med. 379 (4), 341\u2013351 (2018).","journal-title":"N Engl. J. Med."},{"issue":"6","key":"22486_CR35","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","volume":"22","author":"AJ Stratigos","year":"2021","unstructured":"Stratigos, A. J. et al. Cemiplimab in locally advanced basal cell carcinoma after Hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 22 (6), 848\u2013857 (2021).","journal-title":"Lancet Oncol."},{"key":"22486_CR36","doi-asserted-by":"publisher","first-page":"103773","DOI":"10.1016\/j.critrevonc.2022.103773","volume":"177","author":"D Presti","year":"2022","unstructured":"Presti, D. et al. Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: A systematic review. Crit. Rev. Oncol. Hematol. 177, 103773 (2022).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"22486_CR37","doi-asserted-by":"publisher","unstructured":"Ansary, T. M. et al. Immunotherapy for the treatment of squamous cell carcinoma: potential benefits and challenges. Int. J. Mol. Sci., 23(15), 8530 https:\/\/doi.org\/10.3390\/ijms23158530(2022).","DOI":"10.3390\/ijms23158530"},{"issue":"11","key":"22486_CR38","doi-asserted-by":"publisher","first-page":"e1356148","DOI":"10.1080\/2162402X.2017.1356148","volume":"6","author":"EJ de Ruiter","year":"2017","unstructured":"de Ruiter, E. J. et al. The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis. OncoImmunology 6 (11), e1356148 (2017).","journal-title":"OncoImmunology"},{"issue":"5","key":"22486_CR39","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.21037\/jtd-19-3414a","volume":"12","author":"AB Schulze","year":"2020","unstructured":"Schulze, A. B. et al. Tumor infiltrating T cells influence prognosis in stage I\u2013III non-small cell lung cancer. J. Thorac. Disease. 12 (5), 1824\u20131842 (2020).","journal-title":"J. Thorac. Disease"},{"issue":"3","key":"22486_CR40","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/PAI.0b013e31828df3c9","volume":"22","author":"J Santos Pereira","year":"2014","unstructured":"Santos Pereira, J. et al. Analysis of CD8\u2009+\u2009and CD4\u2009+ cells in oral squamous cell carcinoma and their association with lymph node metastasis and histologic grade of malignancy. Appl. Immunohistochem. Mol. Morphology. 22 (3), 200\u2013205 (2014).","journal-title":"Appl. Immunohistochem. Mol. Morphology"},{"key":"22486_CR41","doi-asserted-by":"publisher","unstructured":"Cunha, D. et al. Tumor-Infiltrating T cells in skin basal cell carcinomas and squamous cell carcinomas: global Th1 preponderance with Th17 Enrichment-A Cross-Sectional study. Cells, 13(11), 964 https:\/\/doi.org\/10.3390\/cells13110964(2024).","DOI":"10.3390\/cells13110964"},{"issue":"9","key":"22486_CR42","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth, N., Wicha, M. S. & Zou, W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat. Rev. Immunol. 17 (9), 559\u2013572 (2017).","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"22486_CR43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/2326-6066.CIR-13-0216","volume":"2","author":"HJ Kim","year":"2014","unstructured":"Kim, H. J. & Cantor, H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol. Res. 2 (2), 91\u201398 (2014).","journal-title":"Cancer Immunol. Res."},{"issue":"10","key":"22486_CR44","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1084\/jem.20071190","volume":"205","author":"RA Clark","year":"2008","unstructured":"Clark, R. A. et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J. Exp. Med. 205 (10), 2221\u20132234 (2008).","journal-title":"J. Exp. Med."},{"issue":"7","key":"22486_CR45","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2340\/00015555-2440","volume":"96","author":"SH Omland","year":"2016","unstructured":"Omland, S. H. et al. Immunosuppressive environment in basal cell carcinoma: the role of regulatory T cells. Acta Derm Venereol. 96 (7), 917\u2013921 (2016).","journal-title":"Acta Derm Venereol."},{"key":"22486_CR46","doi-asserted-by":"publisher","unstructured":"Chiang, E. et al. Review of the tumor microenvironment in basal and squamous cell carcinoma. Cancers (Basel), 15(9), 2453https:\/\/doi.org\/10.3390\/cancers15092453 (2023).","DOI":"10.3390\/cancers15092453"},{"issue":"10","key":"22486_CR47","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/ijd.15065","volume":"59","author":"B Beksa\u00e7","year":"2020","unstructured":"Beksa\u00e7, B. et al. Sparsity of dendritic cells and cytotoxic T cells in tumor microenvironment May lead to recurrence in basal cell carcinoma. Int. J. Dermatol. 59 (10), 1258\u20131263 (2020).","journal-title":"Int. J. Dermatol."},{"issue":"1","key":"22486_CR48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.det.2016.07.003","volume":"35","author":"AL Santana","year":"2017","unstructured":"Santana, A. L., Felsen, D. & Carucci, J. A. Interleukin-22 and cyclosporine in aggressive cutaneous squamous cell carcinoma. Dermatol. Clin. 35 (1), 73\u201384 (2017).","journal-title":"Dermatol. Clin."},{"key":"22486_CR49","doi-asserted-by":"publisher","first-page":"116930","DOI":"10.1016\/j.biopha.2024.116930","volume":"177","author":"W Zhang","year":"2024","unstructured":"Zhang, W. et al. Macrophage polarization in the tumor microenvironment: emerging roles and therapeutic potentials. Biomed. Pharmacother. 177, 116930 (2024).","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"22486_CR50","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1600-065X.2008.00607.x","volume":"222","author":"P Allavena","year":"2008","unstructured":"Allavena, P. et al. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol. Rev. 222 (1), 155\u2013161 (2008).","journal-title":"Immunol. Rev."},{"issue":"4","key":"22486_CR51","doi-asserted-by":"publisher","first-page":"243","DOI":"10.5021\/ad.22.042","volume":"35","author":"C Zilberg","year":"2023","unstructured":"Zilberg, C. et al. The immune microenvironment in basal cell carcinoma. Ann. Dermatol. 35 (4), 243\u2013255 (2023).","journal-title":"Ann. Dermatol."},{"issue":"19","key":"22486_CR52","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1002\/cncr.30164","volume":"122","author":"N Donin","year":"2016","unstructured":"Donin, N. et al. Risk of second primary malignancies among cancer survivors in the united States, 1992 through 2008. Cancer 122 (19), 3075\u20133086 (2016).","journal-title":"Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22486-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22486-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22486-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T14:05:05Z","timestamp":1760018705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22486-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22486"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22486-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Approval of the research protocol by an Institutional Reviewer Board: The study was performed in accordance with the Declaration of Helsinki and received ethical approval by the local ethics comity of the Friedrich-Alexander University Erlangen-Nuremberg (Case 54_17Bc). For this type of study formal informed consent is not required, as the research presented consists of a retrospective analysis of tumor tissue collected during routine surgical procedures. No additional tissue sampling was performed for research purposes and the independent ethics committee of the Friedrich-Alexander-University Erlangen-Nuremberg officially waived this requirement.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"35240"}}